Patents by Inventor Ronald V. Abruzzese

Ronald V. Abruzzese has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Gene switch systems employing regulators with decreased dimerization
    Patent number: 7579326
    Abstract: Disclosed is a novel inducible expression system characterized by undetectable biological effect in the absence of an inducer, but which exhibits efficient inducibility in the presence of an inducer.
    Type: Grant
    Filed: March 25, 2003
    Date of Patent: August 25, 2009
    Assignees: Genetronics, Inc., Baylor College of Medicine
    Inventors: Ronald V Abruzzese, Vidya Mehta, Jeffrey L Nordstrom, Jason Fewell, Bert O'Malley, Sophia Tsai
  • CODON OPTIMIZED SYNTHETIC PLASMIDS
    Publication number: 20080194511
    Abstract: One aspect of the current invention is an optimized synthetic mammalian expression plasmid (e.g. pAV0201). This new plasmid comprise a therapeutic element, and a replication element. The therapeutic element of the new plasmid comprises a eukaryotic promoter; a 5? untranslated region (“UTR”); a codon-optimized-eukaryotic therapeutic gene sequence; and a poly adenylation signal. The therapeutic elements of this plasmid are operatively linked and located in a first operatively-linked arrangement. Additionally, the optimized synthetic mammalian expression plasmid comprises replication elements, wherein the replication elements are operatively linked and located in a second operatively-linked arrangement. The replication elements comprise a selectable marker gene promoter, a ribosomal binding site, and an origin of replication. The first-operatively-linked arrangement and the second-operatively-linked arrangement comprise a circular structure of the codon optimized synthetic mammalian expression plasmid.
    Type: Application
    Filed: November 16, 2007
    Publication date: August 14, 2008
    Applicant: VGX PHARMACEUTICLAS, INC.
    Inventors: Ruxandra Draghia-Akli, Ronald V. Abruzzese, Douglas R. Kern
  • Codon optimized synthetic plasmids
    Patent number: 7316925
    Abstract: One aspect of the current invention is an optimized synthetic mammalian expression plasmid (e.g. pAV0201). This new plasmid comprise a therapeutic element, and a replication element. The therapeutic element of the new plasmid comprises a eukaryotic promoter; a 5? untranslated region (“UTR”); a codon-optimized-eukaryotic therapeutic gene sequence; and a poly adenylation signal. The therapeutic elements of this plasmid are operatively linked and located in a first operatively-linked arrangement. Additionally, the optimized synthetic mammalian expression plasmid comprises replication elements, wherein the replication elements are operatively linked and located in a second operatively-linked arrangement. The replication elements comprise a selectable marker gene promoter, a ribosomal binding site, and an origin of replication. The first-operatively-linked arrangement and the second-operatively-linked arrangement comprise a circular structure of the codon optimized synthetic mammalian expression plasmid.
    Type: Grant
    Filed: July 15, 2003
    Date of Patent: January 8, 2008
    Assignee: VGX Pharmaceuticals, Inc.
    Inventors: Ruxandra Draghia-Akli, Ronald V. Abruzzese, Douglas R. Kern
  • Codon optimized synthetic plasmids
    Publication number: 20040092009
    Abstract: One aspect of the current invention is an optimized synthetic mammalian expression plasmid (e.g. pAV0201). This new plasmid comprise a therapeutic element, and a replication element. The therapeutic element of the new plasmid comprises a eukaryotic promoter; a 5′ untranslated region (“UTR”); a codon-optimized-eukaryotic therapeutic gene sequence; and a poly adenylation signal. The therapeutic elements of this plasmid are operatively linked and located in a first operatively-linked arrangement. Additionally, the optimized synthetic mammalian expression plasmid comprises replication elements, wherein the replication elements are operatively linked and located in a second operatively-linked arrangement. The replication elements comprise a selectable marker gene promoter, a ribosomal binding site, and an origin of replication.
    Type: Application
    Filed: July 15, 2003
    Publication date: May 13, 2004
    Applicant: ADVISYS, Inc.
    Inventors: Ruxandra Draghia-Akli, Ronald V. Abruzzese, Douglas R. Kern
  • System for regulation of transgene expression
    Publication number: 20030220286
    Abstract: Disclosed is a novel inducible expression system characterized by undetectable biological effect in the absence of an inducer, but which exhibits efficient inducibility in the presence of an inducer.
    Type: Application
    Filed: March 25, 2003
    Publication date: November 27, 2003
    Inventors: Ronald V. Abruzzese, Vidya Mehta, Jeffrey L. Nordstrom, Jason Fewell, Bert W. O'Malley, Sophia Y. Tsai